Hepatitis B reactivation after chemoimmunotherapy: screen before treatment

Jessica P. Hwang; Alessandra Ferrajoli; Anna S. Lok

doi:10.1016/S0140-6736(21)00210-5

Hepatitis B reactivation after chemoimmunotherapy: screen before treatment

Jessica P. Hwang, Alessandra Ferrajoli, Anna S. Lok

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	510
Number of pages	1
Journal	The Lancet
Volume	397
Issue number	10273
DOIs	https://doi.org/10.1016/S0140-6736(21)00210-5
State	Published - Feb 6 2021

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(21)00210-5

Cite this

@article{d6b42e84eeb640e3a74d1e34f6b23152,

title = "Hepatitis B reactivation after chemoimmunotherapy: screen before treatment",

author = "Hwang, {Jessica P.} and Alessandra Ferrajoli and Lok, {Anna S.}",

note = "Funding Information: ASL served on the advisory board of Gilead; received research funding from Bristol-Myers Squibb, Gilead, and TARGET-RWE; and report consulting fees from Gilead, TARGET-RWE, and GlaxoSmithKline. JPH received research funding from Merck and Gilead. ",

year = "2021",

month = feb,

day = "6",

doi = "10.1016/S0140-6736(21)00210-5",

language = "English (US)",

volume = "397",

pages = "510",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10273",

}

TY - JOUR

T1 - Hepatitis B reactivation after chemoimmunotherapy

T2 - screen before treatment

AU - Hwang, Jessica P.

AU - Ferrajoli, Alessandra

AU - Lok, Anna S.

N1 - Funding Information: ASL served on the advisory board of Gilead; received research funding from Bristol-Myers Squibb, Gilead, and TARGET-RWE; and report consulting fees from Gilead, TARGET-RWE, and GlaxoSmithKline. JPH received research funding from Merck and Gilead.

PY - 2021/2/6

Y1 - 2021/2/6

UR - http://www.scopus.com/inward/record.url?scp=85100439036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100439036&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(21)00210-5

DO - 10.1016/S0140-6736(21)00210-5

M3 - Comment/debate

C2 - 33549195

AN - SCOPUS:85100439036

SN - 0140-6736

VL - 397

SP - 510

JO - The Lancet

JF - The Lancet

IS - 10273

ER -

Hepatitis B reactivation after chemoimmunotherapy: screen before treatment

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this